MedTrace Logo

Serum Alpha-fetoprotein Levels and Response to Direct Antiviral Therapy in Patients With Chronic Hepatitis C

NCT03402165 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1200

Last updated 2018-08-27

No results posted yet for this study

Summary

Alpha-fetoprotein Levels on the Response to direct Antiviral Therapy in Patients with Chronic Hepatitis C

Conditions

  • Hepatitis C

Interventions

DRUG

Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir

Response to DAAD's and developing HCC

Sponsors & Collaborators

  • Sherief Abd-Elsalam

    lead OTHER

Principal Investigators

  • Rehab Badawi, MD · Tanta University

  • Mohamed Alboraie, MD · Al-Azhar University

  • Sherief Abd-Elsalam, MD · Tanta University

  • Mohamed el kassas, MD · Helwan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2022-12-01
Completion
2022-12-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03402165 on ClinicalTrials.gov